Two Cases of Pathological Complete Response to Neoadjuvant Chemoradiation Therapy in Pancreatic Cancer

Yoko Fujii-Nishimura, Ryo Nishiyama, Minoru Kitago, Yohei Masugi, Akihisa Ueno, Koichi Aiura, Shigeyuki Kawachi, Miho Kawaida, Yuta Abe, Masahiro Shinoda, Osamu Itano, Akihiro Tanimoto, Michiie Sakamoto, Yuko Kitagawa

Research output: Contribution to journalArticle

Abstract

Neoadjuvant chemoradiation therapy (NACRT) is increasingly used in patients with a potentially or borderline resectable pancreatic ductal adenocarcinoma (PDA) and it has been shown to improve survival and reduce locoregional metastatic disease. It is rare for patients with PDA to have a pathological complete response (pCR) to NACRT, but such patients reportedly have a good prognosis. We report the clinicopathological findings of two cases of pCR to NACRT in PDA. Both patients underwent pancreatectomy after NACRT (5-fluorouracil, mitomycin C, cisplatin, and radiation). Neither had residual invasive carcinoma and both showed extensive fibrotic regions with several ducts regarded as having pancreatic intraepithelial neoplasia 3/carcinoma in situ in their post-therapy specimens. It is noteworthy that both patients had a history of a second primary cancer. They both had comparatively good outcomes: one lived for 9 years after the initial pancreatectomy and the other is still alive without recurrence after 2 years.

Original languageEnglish
Pages (from-to)26-31
Number of pages6
JournalThe Keio journal of medicine
Volume64
Issue number2
DOIs
Publication statusPublished - 2015

Fingerprint

Neoadjuvant Therapy
Pancreatic Neoplasms
Adenocarcinoma
Pancreatectomy
Second Primary Neoplasms
Carcinoma in Situ
Mitomycin
Fluorouracil
Cisplatin
Radiation
Carcinoma
Recurrence
Survival
Neoplasms

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Fujii-Nishimura, Y., Nishiyama, R., Kitago, M., Masugi, Y., Ueno, A., Aiura, K., ... Kitagawa, Y. (2015). Two Cases of Pathological Complete Response to Neoadjuvant Chemoradiation Therapy in Pancreatic Cancer. The Keio journal of medicine, 64(2), 26-31. https://doi.org/10.2302/kjm.2014-0014-CR

Two Cases of Pathological Complete Response to Neoadjuvant Chemoradiation Therapy in Pancreatic Cancer. / Fujii-Nishimura, Yoko; Nishiyama, Ryo; Kitago, Minoru; Masugi, Yohei; Ueno, Akihisa; Aiura, Koichi; Kawachi, Shigeyuki; Kawaida, Miho; Abe, Yuta; Shinoda, Masahiro; Itano, Osamu; Tanimoto, Akihiro; Sakamoto, Michiie; Kitagawa, Yuko.

In: The Keio journal of medicine, Vol. 64, No. 2, 2015, p. 26-31.

Research output: Contribution to journalArticle

Fujii-Nishimura, Y, Nishiyama, R, Kitago, M, Masugi, Y, Ueno, A, Aiura, K, Kawachi, S, Kawaida, M, Abe, Y, Shinoda, M, Itano, O, Tanimoto, A, Sakamoto, M & Kitagawa, Y 2015, 'Two Cases of Pathological Complete Response to Neoadjuvant Chemoradiation Therapy in Pancreatic Cancer', The Keio journal of medicine, vol. 64, no. 2, pp. 26-31. https://doi.org/10.2302/kjm.2014-0014-CR
Fujii-Nishimura, Yoko ; Nishiyama, Ryo ; Kitago, Minoru ; Masugi, Yohei ; Ueno, Akihisa ; Aiura, Koichi ; Kawachi, Shigeyuki ; Kawaida, Miho ; Abe, Yuta ; Shinoda, Masahiro ; Itano, Osamu ; Tanimoto, Akihiro ; Sakamoto, Michiie ; Kitagawa, Yuko. / Two Cases of Pathological Complete Response to Neoadjuvant Chemoradiation Therapy in Pancreatic Cancer. In: The Keio journal of medicine. 2015 ; Vol. 64, No. 2. pp. 26-31.
@article{4d78eb42add342e3ae128a720fc2797b,
title = "Two Cases of Pathological Complete Response to Neoadjuvant Chemoradiation Therapy in Pancreatic Cancer",
abstract = "Neoadjuvant chemoradiation therapy (NACRT) is increasingly used in patients with a potentially or borderline resectable pancreatic ductal adenocarcinoma (PDA) and it has been shown to improve survival and reduce locoregional metastatic disease. It is rare for patients with PDA to have a pathological complete response (pCR) to NACRT, but such patients reportedly have a good prognosis. We report the clinicopathological findings of two cases of pCR to NACRT in PDA. Both patients underwent pancreatectomy after NACRT (5-fluorouracil, mitomycin C, cisplatin, and radiation). Neither had residual invasive carcinoma and both showed extensive fibrotic regions with several ducts regarded as having pancreatic intraepithelial neoplasia 3/carcinoma in situ in their post-therapy specimens. It is noteworthy that both patients had a history of a second primary cancer. They both had comparatively good outcomes: one lived for 9 years after the initial pancreatectomy and the other is still alive without recurrence after 2 years.",
author = "Yoko Fujii-Nishimura and Ryo Nishiyama and Minoru Kitago and Yohei Masugi and Akihisa Ueno and Koichi Aiura and Shigeyuki Kawachi and Miho Kawaida and Yuta Abe and Masahiro Shinoda and Osamu Itano and Akihiro Tanimoto and Michiie Sakamoto and Yuko Kitagawa",
year = "2015",
doi = "10.2302/kjm.2014-0014-CR",
language = "English",
volume = "64",
pages = "26--31",
journal = "Keio Journal of Medicine",
issn = "0022-9717",
publisher = "Keio University School of Medicine",
number = "2",

}

TY - JOUR

T1 - Two Cases of Pathological Complete Response to Neoadjuvant Chemoradiation Therapy in Pancreatic Cancer

AU - Fujii-Nishimura, Yoko

AU - Nishiyama, Ryo

AU - Kitago, Minoru

AU - Masugi, Yohei

AU - Ueno, Akihisa

AU - Aiura, Koichi

AU - Kawachi, Shigeyuki

AU - Kawaida, Miho

AU - Abe, Yuta

AU - Shinoda, Masahiro

AU - Itano, Osamu

AU - Tanimoto, Akihiro

AU - Sakamoto, Michiie

AU - Kitagawa, Yuko

PY - 2015

Y1 - 2015

N2 - Neoadjuvant chemoradiation therapy (NACRT) is increasingly used in patients with a potentially or borderline resectable pancreatic ductal adenocarcinoma (PDA) and it has been shown to improve survival and reduce locoregional metastatic disease. It is rare for patients with PDA to have a pathological complete response (pCR) to NACRT, but such patients reportedly have a good prognosis. We report the clinicopathological findings of two cases of pCR to NACRT in PDA. Both patients underwent pancreatectomy after NACRT (5-fluorouracil, mitomycin C, cisplatin, and radiation). Neither had residual invasive carcinoma and both showed extensive fibrotic regions with several ducts regarded as having pancreatic intraepithelial neoplasia 3/carcinoma in situ in their post-therapy specimens. It is noteworthy that both patients had a history of a second primary cancer. They both had comparatively good outcomes: one lived for 9 years after the initial pancreatectomy and the other is still alive without recurrence after 2 years.

AB - Neoadjuvant chemoradiation therapy (NACRT) is increasingly used in patients with a potentially or borderline resectable pancreatic ductal adenocarcinoma (PDA) and it has been shown to improve survival and reduce locoregional metastatic disease. It is rare for patients with PDA to have a pathological complete response (pCR) to NACRT, but such patients reportedly have a good prognosis. We report the clinicopathological findings of two cases of pCR to NACRT in PDA. Both patients underwent pancreatectomy after NACRT (5-fluorouracil, mitomycin C, cisplatin, and radiation). Neither had residual invasive carcinoma and both showed extensive fibrotic regions with several ducts regarded as having pancreatic intraepithelial neoplasia 3/carcinoma in situ in their post-therapy specimens. It is noteworthy that both patients had a history of a second primary cancer. They both had comparatively good outcomes: one lived for 9 years after the initial pancreatectomy and the other is still alive without recurrence after 2 years.

UR - http://www.scopus.com/inward/record.url?scp=84960961965&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84960961965&partnerID=8YFLogxK

U2 - 10.2302/kjm.2014-0014-CR

DO - 10.2302/kjm.2014-0014-CR

M3 - Article

VL - 64

SP - 26

EP - 31

JO - Keio Journal of Medicine

JF - Keio Journal of Medicine

SN - 0022-9717

IS - 2

ER -